Close Menu

SAN ANTONIO — Neoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Novartis' Kisqali) and the aromatase inhibitor letrozole (Novartis' Femara) have produced response rates similar to multi-agent chemotherapy in a clinical/molecular subgroup of patients with high-risk Luminal B tumors, according to new study results presented at the San Antonio Breast Cancer Symposium.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.